Open Access

Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells

  • Authors:
    • Tingting Huang
    • Xiaoxiao Luo
    • Bili Wu
    • Ping Peng
    • Yuhong Dai
    • Guangyuan Hu
    • Hong Qiu
    • Xianglin Yuan
  • View Affiliations

  • Published online on: October 21, 2020     https://doi.org/10.3892/or.2020.7820
  • Pages: 2634-2644
  • Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The overexpression or amplification of HER2 has been observed in a significant proportion of both gastric cancer (GC) and breast cancer (BC) cases. Pyrotinib is an irreversible dual (EGFR/HER2) tyrosine kinase inhibitor (TKI), newly evaluated for the treatment of HER2‑overexpressing cancer types. As radiotherapy (RT) serves a crucial role in controlling the local recurrence of GC and BC, the present study investigated the impact of pyrotinib on the irradiation response. The current results demonstrated that pyrotinib enhanced the radiosensitivity of HER2‑overexpressing GC and BC cells in vitro and in vivo. In both NCI‑N87 and SKBR3 cells, pyrotinib suppressed the irradiation‑induced HER2 nuclear transport. Furthermore, pyrotinib increased DNA damage induced by irradiation in both cancer cell lines. Pyrotinib also enhanced the cytotoxicity of docetaxel, which may provide a novel strategy for potential drug combinations. Thus, pyrotinib is a promising irradiation sensitizer in patients with HER2‑overexpressing GC and BC. The present results provide a theoretical foundation for further clinical evaluation of pyrotinib.
View Figures
View References

Related Articles

Journal Cover

December-2020
Volume 44 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Huang T, Luo X, Wu B, Peng P, Dai Y, Hu G, Qiu H and Yuan X: Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells. Oncol Rep 44: 2634-2644, 2020
APA
Huang, T., Luo, X., Wu, B., Peng, P., Dai, Y., Hu, G. ... Yuan, X. (2020). Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells. Oncology Reports, 44, 2634-2644. https://doi.org/10.3892/or.2020.7820
MLA
Huang, T., Luo, X., Wu, B., Peng, P., Dai, Y., Hu, G., Qiu, H., Yuan, X."Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells". Oncology Reports 44.6 (2020): 2634-2644.
Chicago
Huang, T., Luo, X., Wu, B., Peng, P., Dai, Y., Hu, G., Qiu, H., Yuan, X."Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells". Oncology Reports 44, no. 6 (2020): 2634-2644. https://doi.org/10.3892/or.2020.7820